CLEVER HANDELN

Richten Sie Börsennews.de als Startseite ein

Hier klicken

NAM

Der börsennews.de Newsüberblick zum Thema "NAM"

TR ONE-News: Addex to Present at the BIO Investor Forum in San Francisco

07:02 Uhr 24.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

Addex to Present at the BIO Investor Forum in San Francisco

07:01 Uhr 24.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex to Present at the BIO Investor Forum in San Francisco

05:01 Uhr 24.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex to Present at the BIO Investor Forum in San Francisco

05:01 Uhr 24.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

16:02 Uhr 19.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

16:02 Uhr 19.10.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

16:02 Uhr 03.10.2011

... potential to be first-in-class and best-in- class in treating these serious neurological disorders." Dipraglurant-IR, is an mGluR5 negative allosteric modulator, or NAM, which is in Phase IIa testing for PD-LID. Top-line data are expected to be reported in the first half of... weiter lesen

DJ Thomson Reuters ONE/Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

16:01 Uhr 03.10.2011

... potential to be first-in-class and best-in- class in treating these serious neurological disorders." Dipraglurant-IR, is an mGluR5 negative allosteric modulator, or NAM, which is in Phase IIa testing for PD-LID. Top-line data are expected to be reported in the first half of... weiter lesen

Addex Regains Rights to Parkinson's Drug Candidates from Merck

18:06 Uhr 02.09.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and, ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

DJ Thomson Reuters ONE/Addex Regains Rights to Parkinson's Drug Candidates from Merck

16:06 Uhr 02.09.2011

... The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and, ADX71149 (mGluR2 positive allosteric modulator or PAM)... weiter lesen

Mehr zu NAM
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. ›
  7. »